Your browser doesn't support javascript.
loading
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
Rittberg, Rebekah; Leung, Bonnie; Shokoohi, Aria; Pender, Alexandra; Wong, Selina; Al-Hashami, Zamzam; Wang, Ying; Ho, Cheryl.
Afiliación
  • Rittberg R; CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
  • Leung B; BC Cancer Vancouver, Vancouver, BC V5Z 4E6, Canada.
  • Shokoohi A; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.
  • Pender A; The Institute of Cancer Research, London SW7 3RP, UK.
  • Wong S; BC Cancer Victoria, Victoria, BC V8R 6V5, Canada.
  • Al-Hashami Z; Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat 123, Oman.
  • Wang Y; BC Cancer Vancouver, Vancouver, BC V5Z 4E6, Canada.
  • Ho C; BC Cancer Vancouver, Vancouver, BC V5Z 4E6, Canada.
Curr Oncol ; 30(6): 5299-5308, 2023 05 26.
Article en En | MEDLINE | ID: mdl-37366885

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2023 Tipo del documento: Article